Journey Medical Co. (NASDAQ:DERM) Short Interest Up 14.8% in January

Journey Medical Co. (NASDAQ:DERM - Get Free Report) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 76,800 shares, an increase of 14.8% from the December 31st total of 66,900 shares. Approximately 0.8% of the shares of the stock are sold short. Based on an average trading volume of 108,900 shares, the short-interest ratio is currently 0.7 days.

Journey Medical Price Performance

Shares of DERM stock traded down $0.05 during midday trading on Wednesday, reaching $5.30. 27,531 shares of the company traded hands, compared to its average volume of 56,579. The firm's 50 day simple moving average is $4.51 and its two-hundred day simple moving average is $5.05. Journey Medical has a 1-year low of $2.85 and a 1-year high of $6.89. The company has a debt-to-equity ratio of 1.81, a current ratio of 1.38 and a quick ratio of 1.03. The firm has a market cap of $110.72 million, a PE ratio of -5.64 and a beta of 1.03.

Institutional Investors Weigh In On Journey Medical

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. PVG Asset Management Corp increased its stake in shares of Journey Medical by 5.7% during the 3rd quarter. PVG Asset Management Corp now owns 167,545 shares of the company's stock worth $947,000 after purchasing an additional 9,005 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Journey Medical by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company's stock worth $613,000 after purchasing an additional 12,882 shares in the last quarter. ORG Wealth Partners LLC purchased a new position in shares of Journey Medical during the 3rd quarter worth approximately $110,000. Kovitz Investment Group Partners LLC purchased a new position in shares of Journey Medical during the 3rd quarter worth approximately $66,000. Finally, Nwam LLC purchased a new position in shares of Journey Medical during the 3rd quarter worth approximately $59,000. 7.25% of the stock is currently owned by institutional investors and hedge funds.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.